ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Psychiatry

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,000Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 69

$1.43M Total Retail Price of All Prescriptions

Rank: 2 out of 69

416 Patients Receiving at Least One Drug in Part D
26%Patients 65 Years and Older
80% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 416 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

6% of this provider’s 416 patients filled at least one prescription for a schedule three drug, compared to an average of 0%.

Risky Drugs to Seniors

5% of this provider’s 2,014 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$159 was the average price of a prescription from this provider, compared to $142 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
TRAZODONE HCL 533 83 1 2
ABILIFY 476 33 2 4
QUETIAPINE FUMARATE 461 66 3 3
RISPERIDONE 348 207 4 1
ZOLPIDEM TARTRATE 260 60 5 9
MIRTAZAPINE 257 92 6 17
CITALOPRAM HBR 219 64 7 8
ESCITALOPRAM OXALATE 219 69 7 20
DONEPEZIL HCL 218 149 9 32
TOPIRAMATE 213 38 10 22
CYMBALTA 213 38 10 13
LAMOTRIGINE 202 17 12 5
OLANZAPINE 184 34 13 10
GABAPENTIN 175 30 14 18
VENLAFAXINE HCL ER 173 49 15 12
SERTRALINE HCL 172 40 16 6
BUPROPION HCL SR 172 48 16 24
ROPINIROLE HCL 167 15 18 48
LITHIUM CARBONATE 152 0 19 16
BUPROPION XL 150 19 20 19
SEROQUEL 149 28 21 23
FLUOXETINE HCL 149 30 21 14
NAMENDA 131 124 23 41
PRISTIQ ER 130 13 24 33
DIVALPROEX SODIUM ER 128 0 25 15
ZONISAMIDE 126 21 26 53
PAROXETINE HCL 110 35 27 29
RISPERDAL CONSTA 100 0 28 25
AMITRIPTYLINE HCL 98 52 R 29 56
HYDROCODONE-ACETAMINOPHEN 96 23 S3 30 67
METHYLPHENIDATE HCL 95 19 31 44
BENZTROPINE MESYLATE 89 0 R 32 7
DOXEPIN HCL 86 18 33 43
BUSPIRONE HCL 77 19 34 21
ZIPRASIDONE HCL 76 19 35 27
TRIHEXYPHENIDYL HCL 72 15 R 36 35
INVEGA 71 0 37 34
DIVALPROEX SODIUM 70 11 38 26
INVEGA SUSTENNA 69 0 39 42
CHLORPROMAZINE HCL 66 0 40 45
SEROQUEL XR 61 0 41 30
HALOPERIDOL 59 0 42 28
GABITRIL 58 0 43 75
VENLAFAXINE HCL 58 32 43 62
LEXAPRO 55 16 45 46
FLUVOXAMINE MALEATE 54 29 46 38
METHOCARBAMOL 51 0 R 47 79
TRAMADOL HCL 51 16 47 79
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.